• Explore /
  • Poster
  • / Subgroup analysis of the phase II randomized MCL-002 (SPRINT) study of lenalidomide vs investigator’s choice in relapsed/refractory mantle cell lymphoma.

Subgroup analysis of the phase II randomized MCL-002 (SPRINT) study of lenalidomide vs investigator’s choice in relapsed/refractory mantle cell lymphoma.

Abstract Poster

Authors

null

Marek Trneny

Charles University Hospital, Dept. of Hematology, Prague, Czech Republic

Marek Trneny , Thierry Lamy , Jan Andrzej Walewski , David Belada , Jiri Mayer , John A. Radford , Wojciech Jurczak , Franck Morschhauser , Julia Alexeeva , Simon Rule , Tsvetan Nikolov Biyukov , Meera Patturajan , Marie-Laure Casadebaig Bravo , José Cabecadas , Luca Arcaini

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lymphoma and Plasma Cell Disorders

Track

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Sub Track

Lymphoma

Clinical Trial Registration Number

NCT00875667

Citation

J Clin Oncol 33, 2015 (suppl; abstr 8547)

DOI

10.1200/jco.2015.33.15_suppl.8547

Abstract #

8547

Poster Bd #

364

Abstract Disclosures

Similar Posters

First Author: Yucai Wang

First Author: Issa F. Khouri

First Author: V. A. Morrison

First Author: Ian W. Flinn